Stockscreener 앱 받기
5.99
5.67%
-0.36
시간 외 거래:
6.10
0.11
+1.84%
전일 마감가:
$6.35
열려 있는:
$6.25
하루 거래량:
195.21K
Relative Volume:
1.08
시가총액:
$158.79M
수익:
$2.80M
순이익/손실:
$-130.30M
주가수익비율:
-1.1926
EPS:
-5.0228
순현금흐름:
$-79.40M
1주 성능:
-2.60%
1개월 성능:
-18.94%
6개월 성능:
-37.93%
1년 성능:
-49.96%
1일 변동 폭
$5.97
$6.475
1주일 범위
$5.82
$6.475
52주 변동 폭
$5.60
$15.57
Cartesian Therapeutics Inc Stock (RNAC) Company Profile
명칭
Cartesian Therapeutics Inc
전화
301-348-8698
주소
7495 NEW HORIZON WAY, FREDERICK
Compare RNAC vs VRTX, REGN, ARGX, ALNY, ONC
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
RNAC
Cartesian Therapeutics Inc
|
5.99 | 168.33M | 2.80M | -130.30M | -79.40M | -5.0228 |
VRTX
Vertex Pharmaceuticals Inc
|
441.70 | 113.01B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
753.93 | 79.87B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
840.87 | 51.51B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
333.39 | 45.29B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
319.94 | 34.41B | 5.36B | 287.73M | 924.18M | 2.5229 |
Cartesian Therapeutics Inc Stock (RNAC) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-03-09 | 업그레이드 | Cantor Fitzgerald | Neutral → Overweight |
| 2025-07-09 | 개시 | Wedbush | Outperform |
| 2024-12-19 | 개시 | BTIG Research | Buy |
| 2024-08-06 | 개시 | TD Cowen | Buy |
| 2024-07-02 | 다운그레이드 | Oppenheimer | Outperform → Perform |
| 2024-06-04 | 개시 | Oppenheimer | Outperform |
| 2024-05-24 | 개시 | Mizuho | Buy |
| 2024-04-23 | 재확인 | H.C. Wainwright | Buy |
| 2024-04-23 | 개시 | Leerink Partners | Outperform |
| 2023-08-18 | 다운그레이드 | SVB Securities | Outperform → Market Perform |
| 2022-06-14 | 재확인 | Needham | Buy |
| 2022-06-06 | 개시 | SVB Leerink | Outperform |
| 2021-06-15 | 개시 | BTIG Research | Buy |
| 2021-01-26 | 업그레이드 | Mizuho | Neutral → Buy |
| 2020-10-01 | 다운그레이드 | Mizuho | Buy → Neutral |
| 2020-10-01 | 다운그레이드 | William Blair | Outperform → Mkt Perform |
| 2020-06-12 | 다운그레이드 | Stifel | Buy → Hold |
| 2020-04-28 | 개시 | H.C. Wainwright | Buy |
| 2020-01-29 | 개시 | Cantor Fitzgerald | Overweight |
| 2020-01-21 | 개시 | William Blair | Outperform |
| 2018-06-27 | 개시 | Janney | Buy |
| 2017-03-30 | 재확인 | UBS | Buy |
모두보기
Cartesian Therapeutics Inc 주식(RNAC)의 최신 뉴스
Generalized Myasthenia Gravis Market on the Brink of Change: 8 Promising Late-Stage Drugs Signal a New Treatment Era | DelveInsight - GlobeNewswire Inc.
Published on: 2026-04-14 00:35:15 - baoquankhu1.vn
Needham Virtual Healthcare Conference features Cartesian Therapeutics fireside chat on cell therapy - Traders Union
Chart Watch: What chart patterns are forming on Cartesian Therapeutics IncGap Up & Long-Term Growth Plans - baoquankhu1.vn
Today's Analyst Ratings: Needham Reiterates Buy Rating for RNAC - GuruFocus
If You Invested $1,000 in Cartesian (RNAC) - Stock Titan
Trust linked to Cartesian Therapeutics (RNAC) converts preferred into common - Stock Titan
Trust linked to RNAC holder Kalayoglu converts preferred into 758,001 common shares - Stock Titan
Near-20% holder updates Cartesian Therapeutics (RNAC) stake and board role - Stock Titan
Cartesian Therapeutics Announces New Employment Inducement Grants - The Manila Times
RNAC SEC FilingsCartesian 10-K, 10-Q, 8-K Forms - Stock Titan
Published on: 2026-04-01 20:53:55 - baoquankhu1.vn
Big Money Moves: Should I invest in Cartesian Therapeutics Inc before earningsEarnings Summary Report & Smart Allocation Stock Tips - baoquankhu1.vn
RNAC Technical Analysis & Stock Price Forecast - Intellectia AI
Inflation Data: Does Cartesian Therapeutics Inc have declining or rising EPSMarket Weekly Review & Technical Buy Zone Confirmation - baoquankhu1.vn
Cartesian Therapeutics Announces Board Member Murat Kalayoglu Resignation - The Globe and Mail
Merger Talk: Will Cartesian Therapeutics Inc outperform the market in YEAR2026 EndofYear Setup & Entry Point Confirmation Signals - baoquankhu1.vn
Cartesian Therapeutics board member Murat Kalayoglu to resign effective March 31 - Investing.com UK
Cartesian Therapeutics board member Murat Kalayoglu to resign effective March 31 By Investing.com - Investing.com South Africa
Murat Kalayoglu to Resign from Cartesian Board, Leaving Science & Technology Committee - TradingView
Board member Murat Kalayoglu to leave Cartesian Therapeutics (RNAC) board March 31, 2026 - Stock Titan
Cartesian Therapeutics, Inc. Announces Resignation of Murat Kalayoglu, M.D., Ph.D. from the Board, Effective March 31, 2026 - marketscreener.com
Treasury Yields: Why is Cartesian Therapeutics Inc stock going down2026 Volume Leaders & Safe Capital Investment Plans - baoquankhu1.vn
Energy Moves: Is Cartesian Therapeutics Inc benefiting from interest rate changesMarket Activity Recap & Weekly Watchlist for Hot Stocks - baoquankhu1.vn
Aug Patterns: Will Cartesian Therapeutics Inc outperform during market ralliesEarnings Summary Report & Growth Oriented Trading Recommendations - baoquankhu1.vn
Cartesian Therapeutics, Inc. (NASDAQ:RNAC) Receives Consensus Recommendation of "Moderate Buy" from Brokerages - MarketBeat
Trading Action: Will Cartesian Therapeutics Inc outperform during market ralliesPortfolio Gains Report & High Accuracy Buy Signal Tips - baoquankhu1.vn
Swing Trade: Is Cartesian Therapeutics Inc benefiting from interest rate changesQuarterly Profit Summary & Fast Entry High Yield Stock Tips - baoquankhu1.vn
Published on: 2026-03-26 03:38:41 - baoquankhu1.vn
Insiders' US$1.73m Investments In Red Following Cartesian Therapeutics' US$29m Dip In Market Value - simplywall.st
Published on: 2026-03-22 15:23:24 - baoquankhu1.vn
Investment Review: Is Cartesian Therapeutics Inc showing insider buyingWeekly Gains Summary & Risk Controlled Daily Plans - baoquankhu1.vn
Squarepoint Ops LLC Acquires Significant Stake in Cartesian Therapeutics Inc - GuruFocus
Bear Alert: Why is Cartesian Therapeutics Inc stock going downPrice Action & AI Driven Stock Reports - baoquankhu1.vn
Cartesian Therapeutics (RNAC) director Michael Singer gifts 6,555 shares - Stock Titan
Squarepoint entities disclose multi-affiliate stakes in Cartesian Therapeutics (RNAC) — 8.3% each - Stock Titan
Published on: 2026-03-13 09:11:18 - baoquankhu1.vn
RNAC’s Descartes-08 Moves Toward Phase 2 in Rare Muscle Disease: What Investors Should Watch - TipRanks
Cartesian Therapeutics (NASDAQ:RNAC) Receives “Outperform” Rating from Wedbush - Defense World
Analysts Offer Insights on Healthcare Companies: Mineralys Therapeutics, Inc. (MLYS), Cartesian Therapeutics (RNAC) and Vertex Pharmaceuticals (VRTX) - The Globe and Mail
Analysts Offer Insights on Healthcare Companies: Mineralys Therapeutics, Inc. (MLYS), Design Therapeutics (DSGN) and Cartesian Therapeutics (RNAC) - The Globe and Mail
Growth Recap: Does Cartesian Therapeutics Inc have declining or rising EPS2026 Retail Activity & Stock Portfolio Risk Management - baoquankhu1.vn
Analysts Offer Insights on Healthcare Companies: MacroGenics (MGNX) and Cartesian Therapeutics (RNAC) - The Globe and Mail
Wall Street Analysts Are Bullish on Top Healthcare Picks - The Globe and Mail
Myasthenia Gravis Market: Pharma Pipeline Fuels Rapid Expansion by 2034 – DelveInsight | Sanofi, Cartesian Therapeutics, Takeda, UCB Biopharma, Hoffmann-La Roche, Janssen Research & Development, LLC - Barchart
Wedbush Reiterates 'Outperform' Rating on RNAC | RNAC Stock News - GuruFocus
Cantor Fitzgerald upgrades Cartesian Therapeutics (RNAC) - MSN
Cartesian Therapeutics Reports 2025 Financial Results, Advances Descartes-08 Cell Therapy in Autoimmune Diseases and Myasthenia Gravis Phase 3 Trial - Minichart
Cartesian Therapeutics (NASDAQ:RNAC) Upgraded to “Overweight” at Cantor Fitzgerald - Defense World
BTIG reiterates Buy on Cartesian Therapeutics stock, $44 target By Investing.com - Investing.com Canada
Mizuho reiterates Cartesian Therapeutics stock rating on trial progress By Investing.com - Investing.com Canada
Cartesian Therapeutics Inc (RNAC) 재무 분석
매출
순이익
현금흐름
주당 순 이익
2.69%
0.25%
자본화:
|
볼륨(24시간):